Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract

European Journal of Pharmaceutical Sciences

Volumn 52, Issue 1, 2014, Pages 173-179

  Sałaga, Maciej ^a   Sobczak, Marta ^a   Fichna, Jakub ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Abdominal pain; Endogenous cannabinoid system; Fatty acid amide hydrolase; Inflammatory bowel diseases

Indexed keywords

CANNABINOID; CANNABINOID 2 RECEPTOR; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; PF 04457845; PF 3845; PF 465; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ABDOMINAL PAIN; APOPTOSIS; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; COLITIS; DIGESTIVE SYSTEM INFLAMMATION; DRUG STRUCTURE; ENTERITIS; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IRRITABLE COLON; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; WOUND HEALING;

2-ARACHIDONYLGLICEROL (PUBCHEM CID: 5282280); ABDOMINAL PAIN; ANANDAMIDE (PUBCHEM CID: 5281969); ENDOGENOUS CANNABINOID SYSTEM; FATTY ACID AMIDE HYDROLASE; INFLAMMATORY BOWEL DISEASES; N-ARACHIDONOYLPHOSPHATIDYLETHANOLAMINES (PUBCHEM CID: 42626462); N-OLEOYLETHANOLAMINE (PUBCHEM CID: 5283454); PALMIDROL (PUBCHEM CID: 4671); PHOSPHATIDIC ACID (PUBCHEM CID: 5460104); PHOSPHATIDYLETHANOLAMINE (PUBCHEM CID: 160963144);

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOIDS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; PAIN;

EID: 84890263282     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.11.012     Document Type: Review

References (40)

1. K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson, E.T. Lund, R.A. Nugent, T.K. Nomanbhoy, J.P. Alexander, and B.F. Cravatt Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 46 2007 13019 13030 (Pubitemid 350086220)
2. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E. Weerapana, N. Sadagopan, M. Liimatta, S.E. Smith, S. Lazerwith, C. Stiff, S. Kamtekar, K. Bhattacharya, Y. Zhang, S. Swaney, B.K. Van, R.C. Stevens, and B.F. Cravatt Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16 2009 411 420
3. K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, D.T. Dudley, T. Young, P. Wren, Y. Zhang, S. Swaney, B.K. Van, J.L. Blankman, D.K. Nomura, S.N. Bhattachar, C. Stiff, T.K. Nomanbhoy, E. Weerapana, D.S. Johnson, and B.F. Cravatt Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain J. Pharmacol. Exp. Ther. 338 2011 114 124
4. M. Alhouayek, and G.G. Muccioli The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity Trends Mol. Med. 18 2012 615 625
5. L. Booker, S.G. Kinsey, R.A. Abdullah, J.L. Blankman, J.Z. Long, C. Ezzili, D.L. Boger, B.F. Cravatt, and A.H. Lichtman The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice Br. J. Pharmacol. 165 2012 2485 2496
6. M. Camilleri, P. Carlson, S. McKinzie, A. Grudell, I. Busciglio, D. Burton, K. Baxter, M. Ryks, and A.R. Zinsmeister Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation Am. J. Physiol Gastrointest. Liver Physiol. 294 2008 G13 G19
7. A. Chicca, J. Marazzi, S. Nicolussi, and J. Gertsch Evidence for bidirectional endocannabinoid transport across cell membranes J. Biol. Chem. 287 2012 34660 34682
8. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. USA 98 2001 9371 9376 (Pubitemid 32743923)
9. G. D'Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini, and M.V. Di Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation FASEB J. 20 2006 568 570 (Pubitemid 46671252)
10. D. De Filippis, T. Iuvone, A. D'Amico, G. Esposito, L. Steardo, A.G. Herman, P.A. Pelckmans, B.Y. De Winter, and J.G. De Man Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase Neurogastroenterol. Motil. 20 2008 919 927 (Pubitemid 352019711)
11. D.G. Deutsch, and S.A. Chin Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist Biochem. Pharmacol. 46 1993 791 796 (Pubitemid 23272758)
12. D.G. Deutsch, S. Lin, W.A. Hill, K.L. Morse, D. Salehani, G. Arreaza, R.L. Omeir, and A. Makriyannis Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor Biochem. Biophys. Res. Commun. 231 1997 217 221 (Pubitemid 27212141)
13. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949 (Pubitemid 23026736)
14. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz, and D. Piomelli Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 1994 686 691
15. A. Di Sabatino, N. Battista, P. Biancheri, C. Rapino, L. Rovedatti, G. Astarita, A. Vanoli, E. Dainese, M. Guerci, D. Piomelli, S.L. Pender, T.T. Macdonald, M. Maccarrone, and G.R. Corazza The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease Mucosal. Immunol. 4 2011 574 583
16. D. Festi, R. Schiumerini, C. Birtolo, L. Marzi, L. Montrone, E. Scaioli, A.R. Di Biase, and A. Colecchia Gut microbiota and its pathophysiology in disease paradigms Dig. Dis. 29 2011 518 524
17. A. Giuffrida, M. Beltramo, and D. Piomelli Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology J. Pharmacol. Exp. Ther. 298 2001 7 14 (Pubitemid 32574504)
18. E.L. Grigg, S. Kane, and S. Katz Mimicry and deception in inflammatory bowel disease and intestinal behcet disease Gastroenterol. Hepatol. (NY) 8 2012 103 112
19. M. Herkenham, A.B. Lynn, B.R. De Costa, and E.K. Richfield Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Brain Res. 547 1991 267 274
20. J.C. Hoffmann, N.N. Pawlowski, A.A. Kuhl, W. Hohne, and M. Zeitz Animal models of inflammatory bowel disease: an overview Pathobiology 70 2002 121 130
21. A.A. Izzo, and M. Camilleri Cannabinoids in intestinal inflammation and cancer Pharmacol. Res. 60 2009 117 125
22. A.A. Izzo, and K.A. Sharkey Cannabinoids and the gut: new developments and emerging concepts Pharmacol. Ther. 126 2010 21 38
23. G.L. Li, H. Winter, R. Arends, G.W. Jay, V. Le, T. Young, and J.P. Huggins Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects Br. J. Clin. Pharmacol. 73 2012 706 716
24. F. Mule, A. Amato, S. Baldassano, and R. Serio Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon Pharmacol. Res. 56 2007 132 139 (Pubitemid 47302797)
25. P.S. Naidu, L. Booker, B.F. Cravatt, and A.H. Lichtman Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception J. Pharmacol. Exp. Ther. 329 2009 48 56
26. K. Otrubova, C. Ezzili, and D.L. Boger The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH) Bioorg. Med. Chem. Lett. 21 2011 4674 4685
27. R. Pandey, K. Mousawy, M. Nagarkatti, and P. Nagarkatti Endocannabinoids and immune regulation Pharmacol. Res. 60 2009 85 92
28. M.P. Patricelli, and B.F. Cravatt Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism Biochemistry 38 1999 14125 14130
29. B. Pietrzak, A. Dunaj, and K. Piatkowska The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence Postepy Hig. Med. Dosw. (Online) 65 2011 606 615
30. S.E. Plevy, and S.R. Targan Future therapeutic approaches for inflammatory bowel diseases Gastroenterology 140 2011 1838 1846
31. F. Rakhshan, T.A. Day, R.D. Blakely, and E.L. Barker Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells J. Pharmacol. Exp. Ther. 292 2000 960 967 (Pubitemid 30136588)
32. J.C. Sipe, J. Waalen, A. Gerber, and E. Beutler Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) Int. J. Obes. (London) 29 2005 755 759 (Pubitemid 40897010)
33. N. Stella, P. Schweitzer, and D. Piomelli A second endogenous cannabinoid that modulates long-term potentiation Nature 388 1997 773 778 (Pubitemid 27375156)
34. M.A. Storr, C.M. Keenan, D. Emmerdinger, H. Zhang, B. Yuce, A. Sibaev, F. Massa, N.E. Buckley, B. Lutz, B. Goke, S. Brand, K.D. Patel, and K.A. Sharkey Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors J. Mol. Med. (Berlin) 86 2008 925 936
35. W. Strober, I.J. Fuss, and R.S. Blumberg The immunology of mucosal models of inflammation Annu. Rev. Immunol. 20 2002 495 549 (Pubitemid 34293433)
36. T. Sugiura, S. Kondo, A. Sukagawa, T. Tonegawa, S. Nakane, A. Yamashita, Y. Ishima, and K. Waku Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine Eur. J. Biochem. 240 1996 53 62
37. I. Svizenska, P. Dubovy, and A. Sulcova Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review Pharmacol. Biochem. Behav. 90 2008 501 511
38. G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, M. Mor, S. Rivara, P.V. Plazzi, C. Park, S. Kathuria, and D. Piomelli Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 46 2003 2352 2360 (Pubitemid 36637920)
39. K. Wright, N. Rooney, M. Feeney, J. Tate, D. Robertson, M. Welham, and S. Ward Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing Gastroenterology 129 2005 437 453 (Pubitemid 41096632)
40. S. Zeissig, C. Bojarski, N. Buergel, J. Mankertz, M. Zeitz, M. Fromm, and J.D. Schulzke Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment Gut 53 2004 1295 1302 (Pubitemid 39120115)